

## RELEASE

May 31, 2013

Bad Homburg, Germany

### **Fresenius Kabi launches new era in Transfusion Technology**

*Showcasing one of the most cutting-edge and comprehensive transfusion technology product portfolios during the ISBT Meeting in Amsterdam*

It's a new era for transfusion technology. From June 2 to 5 2013, Fresenius Kabi will highlight its expanded transfusion technology portfolio, which now includes the products acquired from Fenwal, under the motto: **"Advancing Transfusion Technology. Together."** Medical transfusion experts will be given their first in-depth look at what has become one of the broadest and most innovative product portfolios in transfusion technology. Fresenius Kabi's outstanding expertise in the separation, collection, filtration, storage and transfusion of blood allows it to collaborate with customers to advance transfusion technology together.

Fresenius Kabi completed the acquisition of Fenwal at the end of 2012. The transaction created a global transfusion technology leader with a comprehensive product portfolio – ranging from manual and automated blood-collection products to a wide variety of related services. In short, Fresenius Kabi offers a vast array of innovative products and services that make it an ideal single source for transfusion technology.

The company's expertise and efforts are aimed at providing products that improve the safety and availability of blood while helping shape the practice of transfusion medicine, making life-saving blood therapies available to the medical professionals and patients worldwide who rely on them. At the ISBT, attendees can get their first overview and demonstration of Fresenius Kabi's comprehensive transfusion medicine portfolio. "We welcome all ISBT attendees to visit our booth and gain insight into our extended product portfolio, our experience and expertise on transfusion technology. Combining the strengths and skills of Fresenius Kabi's transfusion technology business with Fenwal has created a leading-edge product portfolio and the ideal platform to spark innovation in transfusion technology," says Klaus Gögelein, Senior Vice President Transfusion Technology, Region Central/Eastern Europe, Nordics & Middle East at Fresenius Kabi.

ISBT participants will find a broad overview of products to support and help advance transfusion medicine in blood centers, plasma centers and hospitals:

Innovative Separation

- Amicus
- Aurora
- COM.TEC

Donation

- CompoGuard
- CompoLab TS
- CompoSeal Mobilea II

Preparation

- CompoDock
- CompoFlow System
- CompoMat G5
- In-line System

Traceability

- RFID

In addition, Fresenius Kabi will host a product hospitality suite, illustrating how the company supports blood centers and hospitals in the advancement of transfusion medicine.

Fresenius Kabi is looking forward to welcoming you at its booth No. 420 during the ISBT.

###

**Fresenius Kabi** is a leading international health care company focusing on products for the therapy and care of critically and chronically ill patients inside and outside the hospital. We develop, produce and market pharmaceuticals and medical devices. Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for whole blood collection and processing as well as for transfusion medicine and cell therapies. With our corporate philosophy of “caring for life”, we are committed to supporting medical professionals in the best therapy of patients.

Fresenius Kabi has 30,668 employees worldwide (March 31, 2013). In 2012, Fresenius Kabi's sales were €4,539 million and the company's EBIT was €934 million. Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius SE & Co. KGaA.

For more information visit the Company's website at [www.fresenius-kabi.com](http://www.fresenius-kabi.com).

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors,

e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Management Board: Mats Henriksson (Chairman), Marc Crouton, John Ducker, Dr. Christian Hauer, Manfred M. Köhler, Thomas Mechtersheimer, Dr. Michael Schönhofen, Gerrit Steen  
Chairman of the Supervisory Board: Dr. Ulf M. Schneider  
Registered Office: Bad Homburg, Germany  
Commercial Register: Amtsgericht Bad Homburg - HRB 11654

###

**Medical Devices Division**

**Fresenius Kabi AG**

Else-Kröner-Straße 1  
61352 Bad Homburg

Germany

T +49 6172 686 7276

F +49 6172 686 4728

Medical.Devices@fresenius-kabi.com

www.fresenius-kabi.com